Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
23.11B
Market cap23.11B
Price-Earnings ratio
16.50
Price-Earnings ratio16.50
Dividend yield
Dividend yield
Average volume
1.57M
Average volume1.57M
High today
High today
Low today
Low today
Open price
$117.62
Open price$117.62
Volume
0.00
Volume0.00
52 Week high
$119.60
52 Week high$119.60
52 Week low
$67.17
52 Week low$67.17

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $115.65. The company's market cap stands at 23.11B, with a P/E ratio of 16.50.

On 2026-07-21, Incyte(INCY) shares started trading at $117.62, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.57M.

The stock's 52-week range extends from a low of $67.17 to a high of $119.60.

The stock's 52-week range extends from a low of $67.17 to a high of $119.60.

INCY News

TipRanks 10h
Top Incyte Executives Quietly Lock In Profits With Fresh Stock Sales

New insider activity at Incyte ( (INCY) ) has taken place on July 20, 2026. Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make...

MarketWatch 15h
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch

...

Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Nasdaq 24h
Halozyme Partners Incyte To Devolop Subcutaneous Formulations Of INCA033989 Using ENHANZE Technology

(RTTNews) - Biopharmaceutical company Halozyme Therapeutics, Inc. (HALO) announced Monday that it has entered into a global collaboration and license agreement...

Halozyme Partners Incyte To Devolop Subcutaneous Formulations Of INCA033989 Using ENHANZE Technology

Analyst ratings

55%

of 29 ratings
Buy
41.4%
Hold
55.2%
Sell
3.4%

More INCY News

TipRanks 24h
Halozyme announces global collaboration, license agreement with Incyte

Halozyme Therapeutics (HALO) announced that it has entered into a global collaboration and license agreement with Incyte (INCY) to evaluate additional subcutane...

Simply Wall St 2d
Incyte After Fresh Trial Data And ESMO Plans Has Valuation Back In Focus

Incyte (INCY) is back in focus after releasing detailed Phase 1/2 data for latarcibart in von Willebrand disease and flagging fresh oncology updates set for pre...

Incyte After Fresh Trial Data And ESMO Plans Has Valuation Back In Focus
Simply Wall St 3d
Trade Alert: Executive VP Of Incyte Steven Stein Has Sold Stock

We wouldn't blame Incyte Corporation ( ) shareholders if they were a little worried about the fact that Steven Stein, the Executive VP recently netted about US$...

Trade Alert: Executive VP Of Incyte Steven Stein Has Sold Stock
Simply Wall St 4d
Incyte Reports Promising Latarcibart Data As Global Phase 3 Begins

Incyte (NasdaqGS:INCY) reported new Phase 1/2 data for latarcibart (VGA039), a once monthly subcutaneous therapy for von Willebrand disease. The company highli...

Incyte Reports Promising Latarcibart Data As Global Phase 3 Begins
TipRanks 6d
Incyte price target raised to $136 from $124 at BofA

BofA raised the firm’s price target on Incyte (INCY) to $136 from $124 and keeps a Buy rating on the shares. The firm will look for updated guidance on the Q2 e...

Nasdaq 7d
Incyte Now #400 Largest Company, Surpassing Weyerhaeuser

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Incyte Corporation (Symbol: INCY) has taken over the #4...

Incyte Now #400 Largest Company, Surpassing Weyerhaeuser
TipRanks 7d
Incyte: Early Strength in VGA039 Offsets Execution Risks; Salveen Richter Reiterates Hold and $100 Price Target

Goldman Sachs analyst Salveen Richter has maintained their neutral stance on INCY stock, giving a Hold rating yesterday. TipRanks has entered a new arena in th...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.